Oral GLP-1 Agonist Elecoglipron Achieves 11.7% Weight Loss, Rivaling Injections
At ADA 2026, Pfizer's oral small-molecule GLP-1 agonist elecoglipron showed 11.7% placebo-corrected weight loss over 72 weeks without dosing restrictions, while berobenatide demonstrated 14.2% loss with monthly injections, signaling a shift toward diverse GLP-1 delivery routes.
